11/6
04:28 pm
inab
IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights [Yahoo! Finance]
Medium
Report
IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights [Yahoo! Finance]
11/6
04:00 pm
inab
IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Medium
Report
IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights
10/29
08:00 am
inab
IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site
Medium
Report
IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site
10/27
08:00 am
inab
IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications
High
Report
IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications
10/16
06:38 am
inab
IN8bio (NASDAQ:INAB) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
Medium
Report
IN8bio (NASDAQ:INAB) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
10/13
10:59 am
inab
IN8bio (NASDAQ:INAB) was given a new $4.00 price target on by analysts at Mizuho.
Low
Report
IN8bio (NASDAQ:INAB) was given a new $4.00 price target on by analysts at Mizuho.
10/8
12:25 pm
inab
IN8bio (NASDAQ:INAB) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
IN8bio (NASDAQ:INAB) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.